Feature
Letzte Aktualisierung: February 11, 2022
China's mRNA vaccine makes slow progress
On January 24, new data was published from a Phase 1 clinical trial of Arcov, China's most advanced mRNA vaccine candidate (China.Table reported). According to the data, "high concentrations of neutralizing antibodies against live SARS-CoV-2" were found in most subjects after two vaccinations. No severe side effects were recorded. However, the scientists also stated that it is still too early to accurately assess its efficacy.
